<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605148</url>
  </required_header>
  <id_info>
    <org_study_id>TEFA/2015</org_study_id>
    <nct_id>NCT02605148</nct_id>
  </id_info>
  <brief_title>TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function</brief_title>
  <acronym>TEFA</acronym>
  <official_title>TEFA TEDDY Family Prevention - Gluten Free Diet to Preserve Beta-cell Function in Subjects With Islet Autoimmunity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of Gluten Free Diet (GFD) on beta-cell function and glucose metabolism&#xD;
      in subjects with one or several islet autoantibodies without and with dysglycemia at&#xD;
      baseline. Additionally, all subjects will be given treatment with Vitamin D, omega fatty&#xD;
      acids and probiotics.&#xD;
&#xD;
      Subjects will be randomized to GFD or normal diet during 18 months. Beta cell function will&#xD;
      be evaluated at baseline, and during follow-up by glucose tolerance tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The design is a randomized controlled study to determine the safety and the effect of gluten&#xD;
      free diet during 18 months on beta-cell function and glucose metabolism. Lead-in and nonstop&#xD;
      supplement cocktail including vitamin D, omega fatty acids and probiotics will be used to&#xD;
      equalize differences to reduce known confounders. All study subjects will meet with a&#xD;
      dietician to obtain a 3-day diet record and to receive instructions on a healthy normal diet&#xD;
      or GFD.&#xD;
&#xD;
      Subjects (n=60) at 2-49.99 years of age positive for one or several islet autoantibodies will&#xD;
      be recruited. Subjects with one islet autoantibody have done one or several oral glucose&#xD;
      tolerance test (OGTT) prior to the baseline visit. One islet autoantibody positive subjects&#xD;
      are only eligible if they have dysglycemia. All subjects will be randomized based on baseline&#xD;
      intravenous glucose tolerance test (IvGTT) and OGTT into subjects without and with&#xD;
      dysglycemia at baseline.&#xD;
&#xD;
      Beta-cell function and glucose metabolism (alternating IvGTT and OGTT) will be assessed at&#xD;
      baseline and after 6, 12, 18 months of treatment and after 6 months of wash out on a normal&#xD;
      healthy diet.&#xD;
&#xD;
      Adverse events and safety Adverse event will be obtained at visits and during the study,&#xD;
      which will be monitored.&#xD;
&#xD;
      It is expected that subjects with one or several islet autoantibodies will show a loss&#xD;
      compared to baseline of beta-cell function and glucose control. GFD is expected to reduce the&#xD;
      loss in subjects on a healthy diet.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in first phase insulin response (FPIR) from IvGTT</measure>
    <time_frame>24 months</time_frame>
    <description>Change in First phase insulin response from IvGTT during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in area under the curve (AUC) C-peptide</measure>
    <time_frame>24 months</time_frame>
    <description>Change in AUC C-peptide from OGTT during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glucose metabolism</measure>
    <time_frame>24 months</time_frame>
    <description>Change from normal to impaired glucose metabolism during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <description>To evaluate safety of GFD compared to recommended normal diet in the placebo group in subjects supplemented with lead in and nonstop treatment with a cocktail including vitamin D, omega fatty acids and probiotics.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prediabetes</condition>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gluten free diet during 18 months. The subjects will be referred to a nutritionist every 6 months. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal diet. Vitamin D 800 U Daily, Omega 3 fatty acids and probiotics as nutritional supplements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Gluten free diet</intervention_name>
    <description>Gluten free diet during 18 months.</description>
    <arm_group_label>Gluten free diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega 3 fatty acid</intervention_name>
    <description>Omega 3 fatty acid</description>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_label>Normal diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Vitamin D 800 U/day</description>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_label>Normal diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotics</intervention_name>
    <description>Probiotics</description>
    <arm_group_label>Gluten free diet</arm_group_label>
    <arm_group_label>Normal diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects from two (2) to 49,99 years of age.&#xD;
&#xD;
          2. At least one type 1 diabetes-associated autoantibody (to glutamic acid (GADA), insulin&#xD;
             (IAA), insulinoma-associated protein 2 (IA-2A) or zinktransporter 8 (ZnT8R/W/QA) in&#xD;
             subjects with impaired glucose metabolism OR at least two type 1 diabetes-associated&#xD;
             autoantibodies, regardless of normal or impaired glucose metabolism.&#xD;
&#xD;
          3. Written informed consent from research subject. If a child, also from the child's&#xD;
             parents or legal acceptable representative(s) according to local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ongoing treatment with immunosuppressant therapy (topical or inhaled steroids are&#xD;
             accepted).&#xD;
&#xD;
          2. Diabetes.&#xD;
&#xD;
          3. Treatment with any oral or injected anti-diabetic medications.&#xD;
&#xD;
          4. Significantly abnormal hematology results at screening.&#xD;
&#xD;
          5. Participation in other clinical trials with a new chemical entity within the previous&#xD;
             3 months.&#xD;
&#xD;
          6. History of hypercalcemia.&#xD;
&#xD;
          7. Presence of associated serious disease or condition.&#xD;
&#xD;
          8. Diabetes-protective HLA-DQ6-allele.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Månsson Martinez, Nutricionist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lund University, Department of Clinical Sciences Malmö</name>
      <address>
        <city>Malmö</city>
        <zip>20502</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 11, 2015</study_first_submitted>
  <study_first_submitted_qc>November 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Maria Månsson Martinez</investigator_full_name>
    <investigator_title>Study coordinator</investigator_title>
  </responsible_party>
  <keyword>Islet autoimmunity</keyword>
  <keyword>gluten free diet</keyword>
  <keyword>prediabetes</keyword>
  <keyword>prevention</keyword>
  <keyword>type 1 diabetes</keyword>
  <keyword>glucose tolerance test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

